GlobeNewswire by notified

Biotalys Appoints Carlo Boutton as Chief Scientific Officer

Share

Company expands executive team with respected science leader to drive biocontrol innovation

Ghent, Belgium, March 31, 2022 (GLOBE NEWSWIRE) -- Press release

Biotalys (Euronext: BTLS), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions, is pleased to announce the appointment of Dr. Carlo Boutton as Chief Scientific Officer (CSO), effective 3 May 2022.

“I’m delighted to welcome Carlo as a new member of the Executive Committee of Biotalys,” saidSimon Moroney, Chairman of Biotalys. “With a wealth of experience working with antibody innovation and an exemplary track record building world-class research platforms, he is an outstanding addition to the team.”

“The proteins we use in our products are inspired by naturally occurring antibodies, aiming to protect food from the field to the plate,” commentedPatrice Sellès, CEO of Biotalys. “As we continue to develop our technology platform, Carlo will support the acceleration of technical innovation in the next stage of Biotalys’ growth, ensuring we can offer growers safe, effective and sustainable alternatives to conventional crop protection products.”

Most recently serving as the Global Head of Innovation for Large Molecules Research at global healthcare and pharmaceutical leader Sanofi, Dr. Boutton brings more than 20 years of antibody and biochemistry leadership to his new executive role at Biotalys. Reporting to Biotalys’ CEO Patrice Sellès, Dr. Boutton will lead the team’s continued scientific research to further develop the novel AGROBODY Foundry™ technology platform, preparing Biotalys’ pipeline of biofungicides, biobactericides and bio-insecticides for expansion and commercial availability while building its intellectual property portfolio.

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

“Biotalys is at the forefront of innovation in agricultural technology. I could not pass up the opportunity to join Biotalys and apply proven science to address such an important global issue – the safe and sustainable production of our food,” notedDr. Boutton. “Antibody-inspired proteins have the potential to bring completely new compounds and modes of action to farms around the world so we can better protect our crops, consumers and ecosystem. I look forward to working with the exceptionally talented Biotalys team to continue its innovation in AGROBODY™ biocontrols.”

In his most recent role as Sanofi’s Global Head of Innovation, Large Molecules Research, Dr. Boutton drove the innovation strategy and managed an expansive team exploring novel technologies with antibodies, NANOBODIES® and other biologic modalities to find innovative pharmaceutical solutions. Before Sanofi, Dr. Boutton held various scientific leadership roles at Ablynx (now Sanofi), where he focused on bioinformatics, protein modelling and finding new therapeutic applications for its NANOBODY® platform. At Ablynx, he was also involved in multiple strategic partnerships as member of Joint Steering Committees. Previously, he took part in several anti-HIV and anti-HCV drug discovery projects at Tibotec (a subsidiary of Johnson & Johnson). At the start of his career, he contributed to the development of a platform to develop rationally designed therapeutics in the broad field of immunotherapy, at Algonomics (now Lonza). He is named co-inventor on more than 20 patent applications.

Carlo Boutton obtained his M.S. and PhD from the University of Leuven (Belgium), where he researched the physico-chemical behavior of proteins under high-electromagnetic fields.

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company protecting crops and food with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

For further information, please contact

Toon Musschoot, Head of IR & Communication
T: +32 (0)9 274 54 00
E: Toon.Musschoot@biotalys.com

ImportantNotice

This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The Biotalys actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

US Foods Partners With Vertical Farming Innovator Kalera® to Expand Its Local and Sustainable Fresh Produce Portfolio18.5.2022 09:00:00 CEST | Press release

National Vertical Farming Partnership for US Foods Brings Consistent Year-Round Availability of High-Quality Leafy Greens to Customers ROSEMONT, Ill., May 18, 2022 (GLOBE NEWSWIRE) -- US Foods Holding Corp. (NYSE: USFD) today announced a strategic agreement with Kalera®, one of the world’s leading hydroponic indoor vertical farming companies. This is US Foods’ largest vertical farming relationship to date. The agreement underscores US Foods’ commitment to bringing foodservice operators a broad assortment of high-quality produce, year-round. It will also expand the portfolio of local farms that US Foods is sourcing from in various markets in support of its growing Serve Local program. As part of the agreement, Kalera and its wholly owned seed technology business Vindara, will work closely with US Foods to develop and launch new products to US Foods customers in markets across the country. Kalera will bring consistently fresh, sustainable produce year-round to US Foods through its networ

Eolus Vind AB Interim Report 1 January–31 March 202218.5.2022 08:30:00 CEST | Press release

1 January–31 March 2022 Net sales amounted to 432 (242) MSEK.EBIT amounted to -158 (-29) MSEK. Profit before tax amounted to -159 (-21) MSEK.Net profit amounted to -138 (-17) MSEK.Earnings per share, before and after dilution equaled -5.55 (-0.67) SEK.During the period, energy facilities with a total installed capacity of 0 (0) MW were taken into operations and handed over to customer.At the end of the period Eolus had 914 (874) MW under asset management. Significant events during the period Previously communicated delays for Öyfjellet have continued to affect the project and impaired the profitability forecast.Financial goals were communicated based on the business plan for 2022–2024.Eolus placed order for 16 wind turbines with Siemens Gamesa for the projects Skallberget/Utterberget and Tjärnäs in Sweden.Magnus Axelsson was recruited as new Chief Operating Officer.Karin Wittsell Heydl was recruited as Head of Communications, Sustainability and IT. Significant events after the balance

Eolus Vind AB delårsrapport 1 januari–31 mars 202218.5.2022 08:30:00 CEST | Pressemelding

Hässleholm den 18 maj 2022 1 januari–31 mars 2022 Nettoomsättningen uppgick till 432 (242) MSEK.Rörelseresultatet uppgick till -158 (-29) MSEK. Resultat före skatt uppgick till -159 (-21) MSEK.Periodens resultat efter skatt uppgick till -138 (-17) MSEK.Resultat per aktie före och efter utspädning uppgick till -5,55 (-0,67) SEK.Under perioden togs energianläggningar med en total effekt om 0 (0) MW i drift och överlämnades till kunder.Vid periodens utgång omfattade koncernens förvaltningsverksamhet 914 (874) MW. Väsentliga händelser under perioden Tidigare kommunicerade förseningar för Öyfjellet har fortsatt påverka projektet och försämrat lönsamhetsprognosen.Finansiella målsättningar kommunicerades baserade på affärsplan 2022–2024.Eolus lade en order på 16 vindkraftverk hos Siemens Gamesa till projekten Skallberget/Utterberget och Tjärnäs.Magnus Axelsson anställdes som operativ chef och vice VD i moderbolaget.Karin Wittsell Heydl anställdes som chef för kommunikation, hållbarhet och IT.

Snam and Golar LNG sign agreement for an FSRU to supply Sardinia with energy18.5.2022 08:15:00 CEST | Press release

San Donato Milanese (Milan), Bermuda – May, 18, 2022 – Snam and Golar LNG Limited (“Golar”) signed a contract through which Golar will deliver the existing LNG Carrier “Golar Arctic” as a floating storage and regasification unit (FSRU) that Snam will install in the port area of Portovesme, in Sardinia, as part of a project to supply the island with energy. The contract, for a total consideration of 269 million euros, includes the vessel and the capex for Golar to convert the Golar Arctic into an FSRU with storage capacity for up to 140,000 cubic meters. Further to the full conversion of the vessel, the FSRU will be sold to the Snam Group. Start of activities for the conversion of the ship into an FSRU and related fulfillments are subject to Snam’s issuance of a Notice-to-Proceed (NTP) and further to that the conversion is expected to take about two years for the Golar Arctic to be delivered. Forward-Looking Statements This press release contains forward-looking statements (as defined i

Sampo completes its share buyback programme18.5.2022 08:15:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 18 May 2022 at 9:15 am Sampo completes its share buyback programme Sampo plc has now completed its share buyback programme. The repurchases of shares began on 31 March 2022 and ended on 17 May 2022. During that period, Sampo repurchased 4,961,994 of its own shares at an average price per share of EUR 45.85. The amount corresponds to 0.9 per cent of all Sampo plc’s shares. The repurchase of own shares has reduced the company's unrestricted equity by approximately EUR 228 million. The purpose of the buyback programme was to return excess capital to shareholders by reducing Sampo plc’s capital, as the repurchased shares will be cancelled. Management intends to propose to the Board that a new share buyback programme is launched after the Annual General Meeting on 18 May 2022, subject to the AGM renewing the Board authorisation on share repurchases. The Board will make a decision on the proposal at the next regular meeting, which takes place on 9 June 2022.